NVO - Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
2023-12-21 09:45:00 ET
The anti-obesity drug market could be worth $100 billion by 2030, according to analysts from Goldman Sachs . It's a mammoth market and one that looks to be heating up with a growing number of large healthcare companies showing interest in the space. Below, I'll look at some of the top names in the weight-loss market today, and others you may not have realized could be potential rivals in the future.
Two of the biggest names in weight loss today are Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) . Eli Lilly makes Zepbound (tirzepatide) while Novo Nordisk is the name behind Ozempic (semaglutide), its diabetes treatment people have been using off-label for weight loss, and Wegovy (semaglutide), its actual weight-loss drug.
These glucagon-like peptide-1 (GLP-1) agonists help curb appetite and have been rising in popularity, and that trend should continue for the foreseeable future. The early results suggest that Zepbound, also marketed under the name Mounjaro for diabetes, can help people achieve more weight loss than Wegovy. In clinical studies, tirzepatide was able to help patients lose 26.6% of their body weight over 84 weeks. By comparison, patients taking Wegovy lost about 15%, over a shorter period of 68 weeks.
For further details see:
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry